Welcome to our dedicated page for Danaher news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher stock.
Danaher Corporation reports developments tied to its global life sciences and diagnostics businesses, where its companies provide scientific technologies, clinical diagnostic systems and tools used in discovery, diagnosis and therapy development. Recurring updates include earnings calls, dividend actions, investor conference appearances and product or regulatory milestones from operating businesses such as Beckman Coulter Diagnostics.
Company news also covers diagnostic assays, immunoassay analyzer platforms, clinical-laboratory workflows and the Danaher Business System, which the company uses as an operating framework across its businesses. Additional recurring themes include shareholder voting matters, governance updates and capital-structure disclosures.
Danaher Corporation (NYSE: DHR) announced that its 4.75% Series A Mandatory Convertible Preferred Stock will convert into common stock on April 15, 2022. Each share of Preferred Stock will convert at a rate of 6.6632 shares of Common Stock. Holders of record as of March 31, 2022, will also receive a final quarterly cash dividend of $11.875 per share on the Preferred Stock. This move reflects Danaher's commitment to enhancing shareholder value and streamlining capital structure.
Integrated DNA Technologies (IDT) has partnered with Catalytic Data Science as part of its Align Program to enhance next-generation sequencing (NGS) solutions. Catalytic Data Science will promote IDT's rhAmpSeq CRISPR Analysis System, which integrates advanced data analysis technology with IDT's CRISPR genome editing reagents. This collaboration aims to improve the efficiency of genomic research and was highlighted by a 2021 award for innovation. IDT, known for its nucleic acid products, supports over 130,000 life science researchers globally.
Danaher Corporation (NYSE: DHR) will host a quarterly earnings conference call for Q1 2022 on April 21, 2022, at 8:00 a.m. ET. The call can be accessed via webcast on Danaher's website in the Investors section, alongside a presentation. A replay will be available after the call until May 5, 2022, and can be accessed via phone or the website. Danaher, a leader in healthcare and technology, aims to aid customers in overcoming challenges globally, boasting a team of approximately 80,000 associates.
Integrated DNA Technologies (IDT) has announced that the Munich Leukemia Laboratory (MLL) has joined its Align Program, following the launch of IDT's xGen™ NGS portfolio in December. This partnership aims to promote genomics research by leveraging MLL's expertise in sequencing exomes, genomes, and transcriptomes, along with IDT's advanced NGS solutions. MLLSEQ, MLL's sequencing label, will now be available to researchers beyond healthcare. The Align Program enhances access to innovative NGS tools, contributing to advancements in cancer research and diagnostics.
Danaher Corporation (NYSE: DHR) announced that its CEO, Rainer M. Blair, will present at the Cowen Healthcare Conference on March 8, 2022, at 9:10 a.m. ET. The presentation will be available via a live webcast on www.danaher.com. Danaher is a global leader in science and technology, focused on improving quality of life and solving complex challenges across health care, environmental, and applied markets. With over 80,000 associates, Danaher upholds a strong operational culture through its Danaher Business System.
Danaher Corporation (NYSE: DHR) has declared a quarterly cash dividend of $0.25 per share for common stock, payable on April 29, 2022, to shareholders on record by March 25, 2022. Additionally, dividends for preferred stocks include $11.875 for its 4.75% Series A and $12.50 for its 5.00% Series B, both payable on April 15, 2022, to shareholders on record by March 31, 2022. This indicates continued shareholder returns and reflects the company’s confidence in its financial health.
Danaher Corporation (NYSE: DHR) announced strong financial results for Q4 and full year 2021. Q4 net earnings reached $1.8 billion, or $2.39 per share, a 44% increase year-over-year, with revenues of $8.1 billion, up 20.5%. Full year net earnings were $6.3 billion ($8.50 per share), a 74% rise, while revenues increased 32% to $29.5 billion. Operating cash flow rose 34.5% to $8.4 billion. CEO Rainer M. Blair highlighted a transformative year with strategic acquisitions totaling $11 billion and a strong foundation for future growth. The company projects high-single digit core revenue growth for 2022.
Pall Corporation, a subsidiary of Danaher, unveiled the Supralon hydraulic and lube oil filter element range on January 11, 2022. This product upgrade enhances existing filter lines, employing stress-resistant technology for better equipment protection. It promises reduced energy costs and lower maintenance expenses, thereby decreasing total filtration costs. Supralon filters match the form and function of previous models and can retrofit into existing systems to improve fluid cleanliness. The older filter models will be phased out in the coming months.
Danaher Corporation (DHR) announced its CEO, Rainer M. Blair, will discuss the company's strong fourth quarter 2021 results at the J.P. Morgan Healthcare Conference. Core revenue growth is expected to exceed prior guidance, with estimated revenues increasing by high-teens to low-twenties percent year-over-year. This growth is driven by exceptional performance in Life Sciences and Diagnostics, alongside a notable 10% rise in core business. The quarterly earnings call is set for January 27, 2022, to provide further insights.
Danaher Corporation (NYSE: DHR) announced that CEO Rainer M. Blair will present at the J.P. Morgan Healthcare Conference on January 11, 2022, at 11:15 a.m. ET. The presentation will be webcast live and archived on Danaher's website.
Danaher is a global science and technology innovator focused on solving complex challenges in the healthcare, environmental, and applied end-markets. With about 69,000 associates across more than 20 operating companies, Danaher aims to improve quality of life worldwide.